Living With Cancer, a PBS Documentary, Will Air in September

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

MINNEAPOLIS--Living With Cancer: A Message of Hope, a conversation with some of the nearly 10 million US cancer survivors, debuts nationally on PBS, Friday, September 25, at 9:00 pm (check local listings).

MINNEAPOLIS--Living With Cancer: A Message of Hope, a conversation with some of the nearly 10 million US cancer survivors, debuts nationally on PBS, Friday, September 25, at 9:00 pm (check local listings).

Narrated by Anne Bancroft and filmed at the Mayo Clinic Cancer Center, Rochester, Minn, this 1-hour documentary recounts the experiences of cancer survivors, including a 5-year-old leukemia patient and her parents, a cardiologist with testicular cancer, and an ovarian cancer survivor who celebrates "the miracle" of her daughter’s birth. In addition, leading oncologists share new cancer research and provide an overview of causes and preventive steps to lower cancer risk.

The film is being presented on PBS by KTCA-TV, St. Paul/Minneapolis. It debuts on the eve of The March . . . Coming Together to Conquer Cancer, a national cancer awareness event sponsored by the National Coalition for Cancer Sur-vivorship and others. It takes place in Washington, DC, and other cities around the country on September 26.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content